Date and Time
Friday, September 5, 2025
11:47 AM – 12:47 PM Central Time Educational Lunch Meeting
Location
George R Brown Convention Center
1001 Avenida de las Americas
Houston, Texas
Phone: (713) 853-8000
Meeting Room
Level 3 in Grand Ballroom C (Theater Room 2)
There is no registration fee for this event. For the in-person symposium in Houston, Texas preregistration is required as seating is limited.
Faculty Jennifer Crombie, MD
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Laurie H Sehn, MD, MPH
Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Clinical Professor of Medicine
Division of Medical Oncology
University of British Columbia
Podcast Editor, Blood
Vancouver, British Columbia, Canada
Moderator Jeremy S Abramson, MD, MMSc
Director, Center for Lymphoma
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
This activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, Novartis, and Regeneron Pharmaceuticals Inc.
Date and Time
Friday, September 5, 2025
11:47 AM – 12:47 PM Central Time Educational Lunch Meeting
The onsite registration desk will open 15 minutes prior to the session start time.
Module 1: Integrating Bispecific Antibodies into the Management of Follicular Lymphoma (FL) — Dr Crombie
Mechanistic similarities and differences among the various approved and investigational bispecific antibodies targeting CD20 and CD3 for FL
Published efficacy and safety findings from pivotal studies evaluating mosunetuzumab and epcoritamab for patients with relapsed/refractory (R/R) FL
Recent FDA approvals of mosunetuzumab and epcoritamab for patients with FL after 2 or more lines of systemic therapy; optimal incorporation opposite other available options
Key efficacy and safety data with odronextamab in patients with R/R FL
Incidence and severity of cytokine release syndrome (CRS), neurotoxicity and other adverse events (AEs) with bispecific antibody therapy in patients with FL; guideline-endorsed approaches for mitigation and management
Ongoing investigational efforts with mosunetuzumab, epcoritamab and odronextamab, including as first-line treatment and in combination with other anticancer therapies for FL
Module 2: Current Role of CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for FL — Dr Abramson
Principal efficacy and safety outcomes from pivotal studies evaluating axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tis-cel) and lisocabtagene maraleucel (liso-cel) for patients with R/R FL
FDA approvals of axi-cel, tis-cel and liso-cel for R/R FL
Appropriate patient selection and optimal timing in the treatment course for CAR T-cell therapy
Incidence and severity of CRS, neurotoxicity and other acute and longer-term toxicities with available anti-CD19 CAR T-cell constructs for R/R FL
Recommended approaches for monitoring for and managing AEs in patients receiving CAR T-cell therapy
Module 3: Other Recently Approved and Emerging Novel Therapies for R/R FL — Dr Sehn
Biological rationale for the evaluation of tafasitamab for patients with FL
Design, eligibility criteria and recently presented efficacy and safety findings from the Phase III inMIND trial evaluating the addition of tafasitamab to lenalidomide/rituximab (R2) for R/R FL or marginal zone lymphoma
Recent FDA approval of tafasitamab/R2 for patients with R/R FL; current clinical role and optimal sequencing
Biological rationale for the evaluation of Bruton tyrosine kinase inhibitors for R/R FL
Published efficacy and safety data from the Phase II ROSEWOOD study of zanubrutinib in combination with obinutuzumab for patients with FL who had received ≥2 previous systemic therapies
Recent FDA approval of zanubrutinib/obinutuzumab for R/R FL and current clinical role of this approach
Other promising agents and strategies under investigation for patients with R/R FL
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematology-oncology fellows, medical oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of follicular lymphoma (FL).
Learning Objectives
Upon completion of this activity, participants should be able to
Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for patients with relapsed/refractory (R/R) FL.
Develop an understanding of available clinical trial findings supporting the use of bispecific antibodies targeting CD20 and CD3 for the management of R/R FL.
Identify patients with R/R FL who may be candidates for chimeric antigen receptor T-cell therapy directed at CD19.
Assess recently presented clinical research findings with the use of CD19-targeted monoclonal antibodies in combination with immunomodulatory agents in the care of patients with R/R FL.
Evaluate published clinical research findings establishing the efficacy and safety of combined Bruton tyrosine kinase inhibitor/anti-CD20 antibody therapy for patients with R/R FL.
Consider recommended approaches to prevent, ameliorate and manage toxicities associated with various therapies commonly used in the care of patients with R/R FL.
CE Credit
CME/MOC, NCPD and ACPE credit information will be given to each participant as part of the meeting course materials.
Accreditation, Support and Credit Statements
In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute Inc (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour in the area of pharmacology.
Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/SOHO2025/FollicularLymphoma/Sep5/ILNA
Continuing Pharmacy Education
Medical Learning Institute Inc designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-25-032-L01-P
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days and will report your participation to the National Association of Boards of Pharmacy (NABP) only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, view your participation record at the NABP website: https://nabp.pharmacy/
Commercial Support Statement
This CE activity is supported through educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, Novartis, and Regeneron Pharmaceuticals Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This symposium is planned and provided by Medical Learning Institute Inc and Research To Practice. This accredited CME/MOC, NCPD and ACPE activity is an independent satellite symposium in conjunction with the Society of Hematologic Oncology 2025 Annual Meeting and is supported by Bristol Myers Squibb, Genentech, a member of the Roche Group, Novartis, and Regeneron Pharmaceuticals Inc.
Disclosure and Conflict of Interest Policy
Medical Learning Institute Inc and Research To Practice are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy.
Planning Committee and Content/Peer Reviewers — The planners and content/peer reviewers from Medical Learning Institute Inc, the accredited provider, and Research To Practice, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Dr Crombie — Advisory Committees: Genentech, a member of the Roche Group, Regeneron Pharmaceuticals Inc; Consulting Agreements: AbbVie Inc, ADC Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Kite, A Gilead Company, Lilly, Novartis, Regeneron Pharmaceuticals Inc.
Dr Sehn — Consulting/Honoraria: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, CARGO Therapeutics, Chugai Pharmaceutical Co Ltd, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Merck, Seagen Inc; Contracted Research: Genentech, a member of the Roche Group; Data and Safety Monitoring Boards/Committees: CARGO Therapeutics.
MODERATOR — Dr Abramson — Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Celgene Corporation, Foresight Diagnostics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Interius BioTherapeutics, Miltenyi Biotec, Novartis, Roche Laboratories Inc, Seagen Inc; Contracted Research: Bristol Myers Squibb, Celgene Corporation, Cellectis, Genentech, a member of the Roche Group, Merck, Mustang Bio, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc.
SURVEY PARTICIPANTS — John N Allan, MD — Advisory Committees: NeoGenomics; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pharmacyclics LLC, an AbbVie Company; Contracted Research: BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group; Data and Safety Monitoring Boards/Committees: Merck; Speakers Bureaus: AbbVie Inc, BeOne.
Ann LaCasce, MD, MMSc — Advisory Committees: Genmab US Inc, Kite, A Gilead Company; Consulting Agreements: Pierre Fabre, Takeda Pharmaceuticals USA Inc.
Loretta J Nastoupil, MD — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genmab US Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Genentech, a member of the Roche Group; Contracted Research: BeOne, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: Genentech, a member of the Roche Group.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
George R Brown Convention Center
1001 Avenida de las Americas
Houston, TX 77010
Main Phone: (713) 853-8000
Meeting Room
Level 3 in Grand Ballroom C (Theater Room 2)
Directions
The George R Brown Convention Center is the main venue for the SOHO 2025 Annual Meeting.
This activity has been designed to meet the educational needs of hematologists, hematology-oncology fellows, medical oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of follicular lymphoma.
There is no registration fee for this event. For the in-person symposium in Houston, preregistration is required as seating is limited.
NOTICE: In order to attend in person, you must also be registered to attend the SOHO 2025 Annual Meeting. Registration for this event is independent of registration for the 2025 SOHO Annual Meeting.
IN-PERSON Registration
Thank you for your interest in our CME program taking place in Houston, Texas, in conjunction with the 2025 SOHO Annual Meeting. At this time online preregistration for in-person attendance is closed for this event. Seats are still available for the program and will be offered on a first come, first served basis.
Our onsite registration desk will be open at 11:30 AM Central Time on Friday, September 5th. If you are interested in attending, please visit our registration desk outside Level 3 in Grand Ballroom C (Theater Room 2) at the George R Brown Convention Center. Please note: onsite registration does not guarantee meal service, which will be based on availability.
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.
Accreditation, Support and Credit Statements
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.